CytomX Therapeutics, Inc. — Director's Dealing 2021

Jun 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CytomX Therapeutics, Inc. (CTMX)
CIK: 0001501989
Period of Report: 2019-09-30

Reporting Person: McCarthy Sean A. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-30	Common Stock	G	4500	—	Disposed	7809	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	193118	Indirect

Footnotes

F1: Includes 1,006 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2: Amount of securities directly held has been adjusted to reflect the transfer of (i) 2,473 shares pursuant to a domestic relations order on July 9, 2018, (ii) 193,118 shares to Sean A. McCarthy 2018 Trust.

F3: Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.